Recent Updates
Recently added Catalysts
PHAR Positive Sentiment Score: 80/100

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

Tuesday, May 21, 2024 2 min read
Key Takeaway: Pharming Group N.V. successfully held its Annual General Meeting of Shareholders on May 21, 2024, where all proposed measures were approved. Notable outcomes include the reappointment of Barbara Yanni and Mark Pykett as Non-Executive Directors for four years. The shareholders also approved updates to the Remuneration Policy and authorized the Board of Directors to issue and repurchase shares. The meeting reaffirmed strong support from shareholders for the company's strategic direction.

Market Sentiment Analysis

POSITIVE FACTORS

  • All proposals at the AGM were approved, indicating strong shareholder support.
  • Reappointment of experienced directors suggests stability in leadership.
  • Adoption of updated Remuneration Policy could enhance governance practices.
  • Authorization for share issuance and repurchase may support future growth.

Full Press Release Details

Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.
The shareholders approved the proposals to reappoint Ms. Barbara Yanni (agenda item 4.a) and Mr. Mark Pykett (agenda item 4.b), upon binding recommendation of the Board of Directors, as Non-Executive Directors for a period of four years.
In addition, the proposals for the adoption of the updated Remuneration Policy for members of the Board of Directors (agenda item 3), the authorization for the Board of Directors to issue shares and/or options (agenda item 5) and the authorization for the Board of Directors to repurchase shares (agenda item 6) were approved by the shareholders.
A recording of the webcast, presentation slides from today’s AGM, and more details regarding agenda items are available on the Company’s website in the Investor Relations section.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics that are in clinical development. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:
Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Frequently Asked Questions

What proposals were approved at Pharming's AGM?

All proposals, including board member reappointments and new policies, were approved.

Who were reappointed as Non-Executive Directors?

Ms. Barbara Yanni and Mr. Mark Pykett were reappointed for four years.

What is Pharming Group N.V. focused on?

Pharming focuses on therapies for rare, debilitating, and life-threatening diseases.

Where can I find the AGM webcast recording?

The AGM webcast recording is available in the Investor Relations section of the website.

How can I contact Pharming Group?

You can contact Pharming Group via email at investor@pharming.com.

Tags: PHAR Viatris Investor Conferences Healthcare Pharming Group biopharmaceutical AGM shareholders
Last updated: May 21, 2024